Clinical trials
Diabetes (Insulin-requiring, Type 1 or Type 2) clinical trials
Below are recruiting diabetes (insulin-requiring, type 1 or type 2) clinical trials, each written for real people, not researchers. We’re tracking 2,148 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06578624RecruitingPhase 1/Phase 2
SA53-OS for advanced solid tumors
This trial tests an experimental drug (SA53-OS) for people with advanced solid tumors or certain lymphomas whose tumors have a normal p53 gene. The goal is to see if it is safe and helps shrink or slow the cancer.
Canton, OhioAges 18 years+ - NCT06581120Enrolling by invitation
Stomach ultrasound study for diabetes and obesity
This study uses ultrasound to see how GLP-1 RA medications (like Ozempic) affect the stomach in people with type 2 diabetes and obesity. It may help doctors better understand how these medicines work.
Cincinnati, OhioAges 10–25 - NCT06489782Recruiting
New approach to test alcohol use disorder medications
This study tests a new way to quickly screen medications for alcohol use disorder (AUD). You will have lab sessions where your drinking is monitored to see how different medicines affect your alcohol use.
New Haven, ConnecticutAges 21–65 - NCT06463483Recruiting
Automated Insulin Delivery for People with Advanced Kidney Disease
This trial tests an automated insulin pump system for people with diabetes who also have advanced kidney disease. It may help manage blood sugar more easily.
LondonAges 18–70 - NCT06435000Recruiting
A study tracking Stargardt disease progression
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
San Diego, CaliforniaAges 12–65 - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Gilbert, ArizonaAges 18 years+ - NCT06383806Recruiting
Reducing nightmares in adults with narcolepsy
This study tests a new behavioral treatment to reduce nightmares in adults with narcolepsy. It aims to help you sleep better and feel more rested.
Salt Lake City, UtahAges 18 years+ - NCT06370988Recruiting
Theta-burst stimulation for bipolar depression
This study tests a type of brain stimulation (theta-burst TMS) to see if it helps improve depression in people with bipolar disorder. It might be a good option if you have tried medication but still feel depressed.
Toronto, OntarioAges 18–65 - NCT06343805RecruitingPhase 1
Study of LY5830966 for myelofibrosis after JAK inhibitor treatment
This study tests a new drug called LY5830966 for people with myelofibrosis whose disease has not responded to or has returned after treatment with a type I JAK2 inhibitor. The drug aims to help reduce symptoms and improve outcomes.
Palo Alto, CaliforniaAges 18 years+ - NCT06328010Enrolling by invitation
Real-world data registry for wound care treatments
This study collects information on various wound types and how they respond to standard care. It aims to learn what works best for wounds that haven't healed after 4 weeks of treatment.
Scottsdale, ArizonaAges 18 years+ - NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Aurora, ColoradoAges 1–21 - NCT06276374Recruiting
Dual antiplatelet therapy after carotid artery stenting for high bleeding risk
This trial tests if taking two blood thinners (dual antiplatelet therapy) after a carotid artery stenting procedure is safe and effective for patients who have a higher risk of bleeding. It focuses on people with significant blockages in the neck arteries who are also at increased risk for serious bleeding or brain bleeds.
SeoulAges 19 years+ - NCT06261463Recruiting
Peer-led support group for refugee families in Chicago
This study is testing a support program led by trained peers to help refugee families strengthen family bonds and cope with challenges. It is designed for Arabic-speaking families who have recently settled in Chicago.
Chicago, IllinoisAges 12–55 - NCT06230887Enrolling by invitation
New treatment for moral injury in veterans
This study tests a new therapy for veterans struggling with moral injury—distress from events that go against personal values. It compares two treatment approaches to see which works better.
Little Rock, ArkansasAges 18 years+ - NCT06182072RecruitingPhase 1
ProAgio for advanced pancreatic cancer
This trial tests a new drug called ProAgio combined with standard chemotherapy for people with stage IV pancreatic cancer. It aims to see if the combination is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT06210854RecruitingPhase 2
HPV16/18 Vaccine Trial for Cervical Lesions
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
Birmingham, AlabamaAges 18 years+ - NCT06079567Recruiting
Study of FSHD2 progression over 18 months
This study follows people with FSHD2 over 18 months to learn how the disease progresses and affects daily life. No new drugs are tested—just regular check-ups and an MRI scan.
LeuvenAges 18–75 - NCT06042517Recruiting
Ultrasound Nerve Stimulation for Diabetes
This study tests whether focused ultrasound can help people with type 2 diabetes by gently stimulating nerves. It may offer a new way to improve glucose control without medication.
New Haven, ConnecticutAges 18–80 - NCT04999384RecruitingPhase 1
First-in-human dose study for advanced cancers using AN4005
This early study tests AN4005 in adults with advanced or hard-to-treat solid tumors or certain lymphomas. The goal is to find a safe dose and see how the treatment behaves in the body.
Hackensack, New JerseyAges 18 years+ - NCT05938712RecruitingPhase 2
Kidney transplant trial using two diabetes medicines safely
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
Toronto, OntarioAges 18 years+ - NCT05937906RecruitingPhase 1/Phase 2
Chemo and immunotherapy plus short targeted drug for lung cancer
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Dijon, BurgundyAges 18 years+ - NCT05882058RecruitingPhase 2
Dose test of a DLL3 cancer drug for neuroendocrine tumors
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
Mobile, AlabamaAges 18 years+ - NCT05816382RecruitingPhase 2/Phase 3
Testing TAK-861 for narcolepsy type 1 sleepiness
This Phase 2/3 study tests TAK-861 in people with narcolepsy type 1 (NT1) who already completed an earlier TAK-861 trial. The goal is to see if the medicine remains safe and effective for ongoing central (brain-related) sleepiness problems.
Birmingham, AlabamaAges 16–70 - NCT05791864RecruitingPhase 1/Phase 2
Gene therapy for vision loss in CLN2 disease
This study tests a new gene therapy, TTX-381, given as an eye injection to slow or stop vision loss in children with CLN2 disease. It is for children who are already receiving enzyme replacement therapy and are in a stage of rapid vision decline.
HamburgAges 2–7
Hear when a new Diabetes (Insulin-requiring, Type 1 or Type 2) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diabetes (insulin-requiring, type 1 or type 2)?
- Yes. Clin2 currently lists 2,148 recruiting diabetes (insulin-requiring, type 1 or type 2) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diabetes (insulin-requiring, type 1 or type 2) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diabetes (insulin-requiring, type 1 or type 2) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.